Articles related to GYNECOLOGICAL CANCERS

In mice whose immune cells that lack the ability to recognize flagellin, immune therapy induced long-term control of ovarian tumor growth in almost 80% of animals.

A comprehensive analysis of 176,601 cancer cases demonstrates that long-acting reversible contraceptives offer a cancer risk profile comparable to oral contraceptives, with data showing a 20-30% reduction in gynecologic cancer risk and a modest increase in breast cancer risk that returns to baseline after cessation.

Comprehensive genetic profiling now plays a central role in ovarian cancer management, with mandatory offering of both germline and somatic testing for all patients at diagnosis.

Virginia Commonwealth University’s latest research introduces a novel, urine-based test for ovarian cancer, utilizing nanotechnology to identify specific peptides, offering a new avenue for early detection and enhancing patient care strategies.

The recent study on bevacizumab’s effect on ovarian cancer progression provides valuable insights into its initial benefits and subsequent risks.

Selinexor has demonstrated an extraordinary extension in progression-free survival in patients with wild-type TP53 advanced or recurrent endometrial cancer, according to the recent findings from the SIENDO study.